Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of COPD
FEV1 \< 60% predicted
FEV1 \< 70% of FVC
Smoking history of 10 pack-years
You may not be if
Significant other disease than COPD
Recent history of MI (1 year or less)
Cardiac arrhythmia requiring drug therapy
History of asthma, allergic rhinitis or eosinophil count \> 600 mm3
Symptomatic prostatic hypertrophy or bladder neck obstruction
Known narrow-angle glaucoma
Abnormal baseline hematology, blood chemistry or urinalysis
History of cancer within last 5 years
Life-threatening pulmonary obstruction
Cystic fibrosis or bronchiectasis
Tuberculosis
Pulmonary resection
Clareo Health | Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)
